SJEPD030600_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 9.97
- fusion
- other ZFTA
- e1_e2
- E1
- umap1_2d
- -2.114485308
- umap2_2d
- 2.158261105
- umap1_3d
- -0.714804137
- umap2_3d
- 3.283332124
- umap3_3d
- -2.61302787
- dataset
- EPN-StJude
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.893 |
| 2 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.892 |
| 3 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.889 |
| 4 | AUR-AER6-TTM3-A-1-1-R-A742-41 | — | C | 0.885 |
| 5 | 647EE729-B34A-41F0-85AB-207F8C24420B | — | — | 0.884 |
| 6 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.884 |
| 7 | C3L-00913 | — | cohortA4 | 0.882 |
| 8 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.881 |
| 9 | SRR934921 | — | — | 0.880 |
| 10 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.460 | Idelalisib | — uncovered |
| HYPOXIA | 0.450 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.450 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.430 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |